QC
PPH icon

Quadrature Capital’s VanEck Pharmaceutical ETF PPH Stock Holding History

Quadrature Capital’s Portfolio PPH Stock Details PPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-48,853
Closed -$5.04M – 1748
2025
Q4 		$5.04M Buy
+48,853
New +$4.75M 0.05% 217
2025
Q2 		– Sell
-135,786
Closed -$12.4M – 1386
2025
Q1 		$12.4M Buy
135,786
+127,147
+1,472% +$11.5M 0.27% 89
2024
Q4 		$746K Buy
+8,639
New +$781K 0.01% 492
2024
Q3 		– Sell
-4,292
Closed -$392K – 1288
2024
Q2 		$392K Buy
+4,292
New +$383K 0.01% 741

Other funds holding PPH

Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $16B AUM 37.57% 1-Year Est. Return
ERSOT
Employees Retirement System of Texas Austin, Texas $12.6B AUM 31.26% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
JSAM
J. Safra Asset Management New York $2.17B AUM 29.66% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
AT
Avalon Trust Santa Fe, New Mexico $1.63B AUM 42.75% 1-Year Est. Return

Quadrature Capital's PPH Position: Q1 2026 in Review

Quadrature Capital sold out of VanEck Pharmaceutical ETF (PPH) in Q1 2026, closing a stake of 48,853 shares — an estimated $5.04M sold.

Quadrature Capital first reported a position in PPH in Q2 2024 and held it in 4 quarters. The position peaked at $12.4M in Q1 2025. 147 funds tracked by Wall St. Rank hold PPH as of Q1 2026.

  • Quadrature Capital reported no remaining VanEck Pharmaceutical ETF position as of Q1 2026 after selling out during the quarter.
  • Quadrature Capital sold 48,853 VanEck Pharmaceutical ETF shares in Q1 2026, an estimated $5.04M.
  • Quadrature Capital first reported a position in VanEck Pharmaceutical ETF in Q2 2024 and held it in 4 quarters.
  • Quadrature Capital's VanEck Pharmaceutical ETF position peaked at $12.4M in Q1 2025.
  • 147 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.